Related Experiment Video
Updated: Dec 15, 2025
07:23
Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography
Published on: March 26, 2020
8.6K
Anti-integrin therapy for retinovascular diseases
Ashay D Bhatwadekar1, Viral Kansara2, Qianyi Luo1
1Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University , Indianapolis, IN, USA.
Expert Opinion on Investigational Drugs
|July 14, 2020
Summary
Integrin inhibitors show promise for treating retinal diseases like diabetic macular edema and age-related macular degeneration. These agents offer potential as primary, adjunctive, or secondary therapies for various ocular conditions.
Area of Science:
- Ophthalmology
- Molecular Biology
- Pharmacology
Background:
- Integrins are crucial cell-adhesion molecules mediating cell-extracellular matrix interactions.
- These receptors regulate fundamental cellular processes including adhesion, migration, and apoptosis.
- Integrins are implicated in pathological processes such as inflammation, angiogenesis, and fibrosis.
Purpose of the Study:
- To review anti-integrin agents for retinal diseases.
- To summarize preclinical and clinical data on these agents.
- To explore therapeutic potential in diabetic retinopathy and age-related macular degeneration.
Main Methods:
- Examination of anti-integrin agents' chemical nature, administration routes, and mechanisms of action.
- Review of preclinical and clinical study data.
- Identification of current clinical and preclinical candidates.
Main Results:
- Current clinical candidates (risuteganib, THR-687, SF-0166) show promise for diabetic macular edema (DME) and age-related macular degeneration (AMD).
- Preclinical candidates demonstrate reduction in retinal permeability, angiogenesis, and choroidal neovascularization (CNV).
Conclusions:
- Anti-integrin therapies hold significant potential for treating retinal diseases.
- These agents address the complex nature of diabetic retinopathy (DR) and AMD.
- Integrin inhibition may serve as primary, adjunctive, or refractory case therapy.
Related Concept Videos
01:15Activation of Integrins
4.7K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.7K
01:17Intracellular Signaling Affects Focal Adhesions
3.3K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.3K
01:27Open Angle Glaucoma: Treatment
869
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
869
01:29Venous Thrombosis III: Interprofessional Care
189
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
189
01:10Integrins
4.9K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
352
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
352